Update on PALLAS triaI evaluating adjuvant palbociclib for early breast cancer
 

The Austrian Breast & Colorectal Cancer Study Group, Alliance Foundation Trials, the Breast International Group, PrECOG, LLC, the German Breast Group, and the NSABP Foundation today announced that the independent Data Monitoring Committee for the global Phase 3 early breast cancer PALbociclib CoLlaborative Adjuvant Study trial determined that the study is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival following a preplanned interim analysis.

More...